Superworth

Dianthus Therapeutics EPS DNTH

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$4.15
Latest quarter, Q2 FY26
−$0.90
Fiscal year 2025
−$4.10

Dianthus Therapeutics' earnings per share was −$4.15 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.90.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$4.10n/a
FY2024−$2.59n/a
FY2023−$25.32n/a
FY2022−$25.06n/a
FY2021−$20.96n/a
FY2020−$27.84n/a
FY2019−$32.80n/a
FY2018−$138.40n/a
FY2017−$312.32n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.90n/a−$4.15
Q1 FY26−$0.85n/a−$4.13
Q4 FY25−$1.43n/a−$4.10
Q3 FY25−$0.97n/a−$3.47
Q2 FY25−$0.88n/a−$3.24
Q1 FY25−$0.82n/a−$2.87
Q4 FY24−$0.80n/a−$2.59
Q3 FY24−$0.74n/a−$2.50
Q2 FY24−$0.51n/a−$5.54
Q1 FY24−$0.54n/a−$17.76
Q4 FY23−$0.71n/a−$25.32
Q3 FY23−$3.78n/a−$29.89

Against its peers

Companies in Drug Manufacturers - General nearest Dianthus Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
DNTHDianthus Therapeutics−$4.15
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
LQDALiquidia$1.39
OGNOrganon$0.77−71% a year
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
AMRXAmneal Pharmaceuticals$0.49+4800% a year
NRIXNurix Therapeutics$2.31
ALKSAlkermes plc.$0.38−82% a year
PBHPrestige Consumer Healthcare$3.57−16% a year
Peer median$1.18

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Dianthus Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.